A multidisciplinary program for meningioma treatment, research, and support services
Clicks: 3
ID: 315134
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #18 of 43 articles by views in Neuro-Oncology Practice
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Standard treatments for meningioma include surgery and radiotherapy, but the timing and technical details of these treatments are debated, particularly as advances in understanding of meningioma biology are expanding options for treatment. Patients with meningioma may experience adverse quality-of-life and neurocognitive sequelae following diagnosis and treatment, and survivorship resources for these patients are limited. Methods We initiated a Multidisciplinary Meningioma Program (MMP) to advance the care of patients at our institution in September 2024. The MMP consists of synergistic clinical, scientific, and survivorship resources, including a weekly tumor board and multidisciplinary clinic, clinical trials and prospective registries for translational research, a meningioma-specific support group, and basic and translational research. In this article, we describe the implementation and initial patient-facing aspects of the MMP. Results In the first 15 months of the MMP, 602 cases were discussed at the MMP tumor board, and 142 patients were seen in consultation in the MMP multidisciplinary clinic. Twelve percent of patients discussed in the MMP tumor board were offered clinical trial enrollment, and 84% were offered prospective registry enrollment. Participants in the MMP support group cited informational and emotional benefits. Following implementation of the MMP, the clinical volume of consultations for meningioma increased by 87.0–533.3%, and the volume of treatments increased by 42.1–115.2% across clinical departments. Conclusions Through creation of a multidisciplinary program for meningioma treatment, research, and support services, we enabled consensus clinical recommendations, streamlined enrollment on clinical trials and prospective registries, improved access to support services, and increased patient volume.
| Reference Key |
openalex_W7162497621
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Zora Arum, Ramin A Morshed, Brooke C Braman, Kanish Mirchia, Javier E Villanueva-Meyer, Vaughn Mouton, Tracy Ward, Charlotte Huie, Jennifer Viner, Alon Witztum, Molly Rose Morrissey, Ashley Bazell, Stephanie Lewis, Linda Pham, Sasha Mortezaei, Melike Pekmezci, Jacob S Young, Lauren Boreta, Matthew Susko, Jean L. Nakamura, Steve Braunstein, Marc H. Levin, Shawn L Hervey-Jumper, Tarun Arora, Manish K Aghi, Tina R Jimenez, Christina Weyer-Jamora, Arie Perry, Penny K. Sneed, John F De Groot, Edward F. Chang, Naomi Hoffer, Susan M Chang, Mitchel S Berger, Michael W Mcdermott, Philip V. Theodosopoulos, William C Chen, Nancy Ann Oberheim Bush, David R Raleigh |
| Journal | Neuro-Oncology Practice |
| Year | 2026 |
| DOI |
10.1093/nop/npag051
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.